Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India

MUMBAI - Seventeen years after Prograf (tacrolimus) was first introduced into the market, Japan's second largest drug maker, Astellas Pharma, is still counting heavily on its blockbuster transplant drug to push future growth